Last reviewed · How we verify
NCT05463523
A Multi-centric Clinical Trial in China for Skin Diseases Intelligent Diagnosis and Treatment System
trial testing A Real-time Augmented Reality Device with Artificial Intelligence Integration in Skin Diseases in 200 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Xiangya Hospital of Central South University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 15 April 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- A Real-time Augmented Reality Device with Artificial Intelligence Integration
Conditions studied
- Skin Diseases — all drugs for Skin Diseases →
- Artificial Intelligence — all drugs for Artificial Intelligence →
- Augmented Reality — all drugs for Augmented Reality →
- Medical Imaging — all drugs for Medical Imaging →
Sponsor
Xiangya Hospital of Central South University
Who can join
Eligibility, any sex, with Skin Diseases or Artificial Intelligence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In response to clinical needs, infrared multi-spectral images are combined with traditional clinical images and other multi-modal data to build a more efficient intelligent auxiliary diagnosis system and intelligent equipment for skin health and diseases, including skin lesions automatically segmentation on skin diseases images, automatically design surgical margin and planning for skin tumor surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05463523
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Skin Diseases
Currently open trials in the same condition.
- NCT07412691 — A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases · Phase 1 · recruiting
- NCT07091604 — An Observational Study to Assess Objective Skin Pigmentation Variation. · recruiting
- NCT07158879 — Skin Reactions Related to Thoracic Implantable Chamber Dressings · recruiting
- NCT06850311 — Herbal Ointment in Treating Atopic Dermatitis Topically · Phase 2, PHASE3 · recruiting
- NCT06563323 — Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) · Phase 2 · recruiting
Other Xiangya Hospital of Central South University trials
Trials by the same sponsor.
- NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
- NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
- NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
- NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
- NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05463523 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
- Last refreshed: 21 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05463523.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing